REG - Venture Life Group - Lloyds Pharmacy to list UltraDEX in UK

Venture LifeAnnouncement

04/06/2018 07:05

RNS Number : 1086Q
Venture Life Group PLC
04 June 2018
 


Venture Life Group plc
("Venture Life" or the "Company")
 
Lloyds Pharmacy to list UltraDEX in UK
New international partnering deal signed
 
Venture Life (AIM: VLG), the international consumer self-care company focused on developing, manufacturing and commercialising products for the self-care market, announces an update on the UltraDEX brand and a new international distribution agreement for the Myco Clear brand.
 
The Company announces the launch of UltraDEX in Lloyds Pharmacy in the UK from 18 June 2018. Initially, this will bring the brand an additional 580 new listings through the introduction in stores of UltraDEX Oral Rinse and UltraDEX Fresh Breath spray. In addition, Lloyds Pharmacy will list these two products, plus the UltraDEX Toothpaste in their online store, where it will be available to purchase online or via click and collect in store.
 
Lloyds Pharmacy is a leading community pharmacy and healthcare provider with over 1,500 pharmacies across the UK, mainly in community and health centre locations.
 
In addition, and as previously announced, Superdrug is launching the new UltraDEX One GOÔ range in 797 stores in the UK from 4 June 2018. UltraDEX One GOÔ is a new and innovative line extension from the Company, providing single use sachets of the clinically proven UltraDEX mouthwash.  
 
Separately, the Company also announces a new distribution deal with the international pharmaceutical company Jaba Recordati S.A. ("Jaba") in Portugal for Myco Clear™, a range that helps treat and prevent nail fungal infections. Launch will take place later this year, or Q1 2019.
 
Commenting Chief Executive Officer, Jerry Randall, said: "I am delighted that we have now been able to get the UltraDEX range into Lloyds Pharmacy, the second largest chain of pharmacies in the UK. Our store listings are now 20% higher than one year ago - this reflects the continued commercial development of the UltraDEX brand in the UK. This increase of distribution also illustrates the growing momentum of the brand along with the launch of the new UltraDEX One GOÔ in Superdrug. We have seen a high level of interest in the new products developed for the UltraDEX range and expect to provide further news in this area soon."
 
I am also delighted to announce the new distribution agreement of Myco Clear™ with Jaba, who are a significant player in the European OTC market. This opportunity adds to a number of products we already supply to the Recordati Group. The adoption of Myco Clear™ by such a prestigious company validates the innovative and high quality nature of our products in this area."
 
 
 For further information please contact:
 



Venture Life Group PLC


+44 (0) 1344 742870




Jerry Randall, Chief Executive Officer








Adrian Crockett, Chief Financial Officer   




























Northland Capital Partners Limited (Nominated Adviser and Joint Broker)


+44 (0) 20 3861 6625




Matthew Johnson / Edward Hutton (Corporate Finance)








John Howes / Vadim Alexandre (Corporate Broking) 




























Turner Pope Investments (TPI) Ltd (Joint Broker)


+44 (0) 20 3621 4120




James Pope / Ben Turner




























Walbrook PR


venturelife@walbrookpr.com or + 44 (0) 20 7933 8780




Anna Dunphy /Paul McManus


+44 (0) 7876 741 001 / +44 (0) 7980 541 893

















 
About Venture Life (www.venture-life.com) 
Venture Life is an international consumer self-care company focused on developing, manufacturing and commercialising products for the ageing population. The Group's product portfolio includes some key products such as the UltraDEX oral care products range, food supplements for lowering cholesterol and maintaining brain function, medical devices for women's intimate healthcare and haemorrhoids and dermo-cosmetics for addressing the signs of ageing.
The products, which are typically recommended by pharmacists or healthcare practitioners, are available primarily through pharmacies supplied by the Group's international distribution partners. 
Through its Development & Manufacturing business in Italy, Biokosmes, the Group also provides development and manufacturing services to companies in the medical devices and cosmetic sectors. 
 




This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
MSCMMGGVRMDGRZM